| Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies (NCT05290155) | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | 2022-05-04 |
| An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD30+ Relapsed/Refractory Lymphoma (NCT05208853) | Zhejiang University | 2022-02-10 |
| Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies (NCT04195633) | Fred Hutchinson Cancer Center | 2021-01-25 |
| A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma (NCT03947255) | Seagen Inc. | 2019-10-28 |
| Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies (NCT04008394) | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2019-07-03 |
| Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies (NCT03905135) | National Cancer Institute (NCI) | 2019-06-07 |
| Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas (NCT03598998) | City of Hope Medical Center | 2019-02-04 |
| Phase I/II Study Evaluating AUTO4 in Patients With T Cell Receptor Beta Constant (TRBC)1 Positive T Cell Lymphoma (NCT03590574) | Autolus Limited | 2018-08-30 |
| Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell Lymphoma (NCT03534180) | City of Hope Medical Center | 2018-08-21 |
| Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms (NCT03493451) | BeiGene | 2018-04-13 |
| Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma and Other CD30+Peripheral T-Cell Lymphomas (NCT03205891) | M.D. Anderson Cancer Center | 2018-03-01 |
| CD30 Targeted CAR-T in Treating CD30-Expressing Lymphomas (NCT03383965) | Immune Cell, Inc. | 2017-03-01 |
| Vinorelbine for Recurrent ACLC (NCT03397953) | Children's Cancer Group, China | 2016-11-01 |
| Vinorelbine for Recurrent ALCL-2017 (NCT03443128) | Children's Cancer Group, China | 2016-11-01 |
| Ceritinib Rare Indications Study in ALK+ Tumors (NCT02465528) | Novartis Pharmaceuticals | 2016-05-06 |
| Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma (NCT02652715) | Mayo Clinic | 2016-01-19 |
| Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma (NCT02232516) | Northwestern University | 2015-06-11 |
| Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma (NCT01769911) | Fred Hutchinson Cancer Center | 2015-02-01 |
| CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma (NCT02168140) | Wake Forest University Health Sciences | 2014-09-01 |
| Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant (NCT01959477) | Case Comprehensive Cancer Center | 2014-03-01 |
| Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies (NCT01652014) | University of Medicine and Dentistry of New Jersey | 2014-01-01 |
| MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma (NCT01748721) | Morphotek | 2013-11-01 |
| A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma (NCT01950364) | Millennium Pharmaceuticals, Inc. | 2013-11-01 |
| Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma (NCT01943682) | Children's Hospital Medical Center, Cincinnati | 2013-09-01 |
| Blood Sample Markers of Reproductive Hormones in Assessing Ovarian Reserve in Younger Patients With Newly Diagnosed Lymphomas (NCT01793233) | Children's Oncology Group | 2013-06-17 |
| Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency (NCT01787409) | Mayo Clinic | 2013-03-06 |
| Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas (NCT01805037) | Northwestern University | 2013-03-05 |
| Ipilimumab and Local Radiation for Selected Solid Tumors (NCT01769222) | Stanford University | 2013-02-01 |
| ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas (NCT01777152) | Seagen Inc. | 2013-01-31 |
| Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant (NCT01588015) | City of Hope Medical Center | 2012-10-29 |
| Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL (NCT01686165) | University of Arizona | 2012-08-31 |
| Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL) (NCT01657331) | Columbia University | 2012-07-01 |
| Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma (NCT01567709) | National Cancer Institute (NCI) | 2012-04-16 |
| Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies (NCT01529827) | Roswell Park Cancer Institute | 2012-02-28 |
| Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma (NCT01466881) | National Cancer Institute (NCI) | 2011-10-01 |
| Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies (NCT01427881) | Fred Hutchinson Cancer Center | 2011-09-01 |
| Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma (NCT01336933) | University of Nebraska | 2011-07-06 |
| Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors (NCT01326702) | National Cancer Institute (NCI) | 2011-07-01 |
| Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma (NCT01336920) | University of Nebraska | 2011-06-21 |
| Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies (NCT01658319) | Case Comprehensive Cancer Center | 2011-05-01 |
| Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NCT01261247) | Mayo Clinic | 2011-01-17 |
| Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma (NCT01075321) | Mayo Clinic | 2011-01-10 |
| Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies (NCT01273766) | Wake Forest University Health Sciences | 2011-01-01 |
| Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant (NCT01199562) | City of Hope Medical Center | 2010-12-01 |
| Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma (NCT01258998) | National Cancer Institute (NCI) | 2010-12-01 |
| Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers (NCT01254578) | National Cancer Institute (NCI) | 2010-11-24 |
| Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma (NCT01110135) | University of Washington | 2010-08-01 |
| RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors (NCT01158274) | National Cancer Institute (NCI) | 2010-06-01 |
| Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma (NCT01129180) | Pierluigi Porcu | 2010-05-01 |
| Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma (NCT01116154) | City of Hope Medical Center | 2010-05-01 |
| Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy (NCT00890747) | National Cancer Institute (NCI) | 2009-08-01 |
| FAU in Treating Patients With Advanced Solid Tumors or Lymphoma (NCT00769288) | National Cancer Institute (NCI) | 2009-07-01 |
| Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma (NCT00918333) | Mayo Clinic | 2009-06-01 |
| Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders (NCT00856388) | Roswell Park Cancer Institute | 2009-01-14 |
| Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery (NCT00608361) | National Cancer Institute (NCI) | 2008-10-01 |
| Study of MLN8237 in Participants With Advanced Hematological Malignancies (NCT00697346) | Millennium Pharmaceuticals, Inc. | 2008-07-11 |
| Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma (NCT00644189) | Massachusetts General Hospital | 2008-06-01 |
| Lenalidomide Therapy for Patients With Relapsed and/or Refractory, Peripheral T-Cell Lymphomas (NCT00704691) | University of Alabama at Birmingham | 2008-06-01 |
| Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma (NCT00720135) | City of Hope Medical Center | 2008-01-01 |
| Safety Study of XmAb®2513 to Treat Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma (NCT00606645) | Xencor, Inc. | 2007-12-01 |
| Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma (NCT00601718) | University of Washington | 2007-12-01 |
| Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction (NCT00499811) | National Cancer Institute (NCI) | 2007-06-01 |
| Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma (NCT00458731) | National Cancer Institute (NCI) | 2007-05-01 |
| Ifosfamide, Carboplatin, Etoposide, and SGN-30 in Treating Young Patients With Recurrent Anaplastic Large Cell Lymphoma (NCT00354107) | National Cancer Institute (NCI) | 2007-01-01 |
| SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma (NCT00365274) | National Cancer Institute (NCI) | 2006-08-01 |
| 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma (NCT00293345) | National Cancer Institute (NCI) | 2006-06-01 |
| PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma (NCT00354185) | National Cancer Institute (NCI) | 2006-05-01 |
| A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies (NCT00343798) | Fred Hutchinson Cancer Center | 2006-04-01 |
| PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas (NCT00348985) | National Cancer Institute (NCI) | 2006-03-01 |
| Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma (NCT00310128) | AIDS Malignancy Consortium | 2006-02-01 |
| Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma (NCT00112723) | National Cancer Institute (NCI) | 2005-12-01 |
| Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma (NCT00131937) | National Cancer Institute (NCI) | 2005-10-01 |
| Sorafenib in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (NCT00278382) | National Cancer Institute (NCI) | 2005-10-01 |
| 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer (NCT00103272) | National Cancer Institute (NCI) | 2005-04-01 |
| Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer (NCT00118352) | Fred Hutchinson Cancer Center | 2005-03-01 |
| Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas (NCT00096005) | National Cancer Institute (NCI) | 2004-11-01 |
| MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas (NCT00098891) | National Cancer Institute (NCI) | 2004-10-01 |
| 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas (NCT00089271) | National Cancer Institute (NCI) | 2004-07-01 |
| Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer (NCT00089011) | Fred Hutchinson Cancer Center | 2004-04-01 |
| Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma (NCT00082888) | National Cancer Institute (NCI) | 2004-03-24 |
| Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent Anaplastic Large Cell Lymphoma (NCT00079755) | Seagen Inc. | 2004-02-01 |
| Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma (NCT00077155) | National Cancer Institute (NCI) | 2003-12-01 |
| Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant (NCT00078858) | Fred Hutchinson Cancer Center | 2003-09-01 |
| Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies (NCT00072514) | Fred Hutchinson Cancer Center | 2003-08-01 |
| Ixabepilone in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (NCT00058019) | National Cancer Institute (NCI) | 2003-02-01 |
| Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer (NCT00049504) | Fred Hutchinson Cancer Center | 2002-01-01 |
| Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction (NCT00025415) | National Cancer Institute (NCI) | 2001-08-01 |
| S0108 Bevacizumab in Treating Patients With Non-Hodgkin's Lymphoma (NCT00016094) | National Cancer Institute (NCI) | 2001-04-01 |
| Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies (NCT00014235) | Fred Hutchinson Cancer Center | 2000-12-01 |
| 506U78 in Treating Patients With Lymphoma (NCT00005080) | National Cancer Institute (NCI) | 2000-05-01 |
| Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer (NCT00112593) | Fred Hutchinson Cancer Center | 1999-11-01 |
| 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma (NCT00004241) | National Cancer Institute (NCI) | 1999-10-01 |
| Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies (NCT01678443) | Fred Hutchinson Cancer Center | 1999-09-01 |
| Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NCT00073918) | Fred Hutchinson Cancer Center | 1999-02-01 |
| Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma (NCT00003970) | National Cancer Institute (NCI) | 1999-01-01 |
| Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma (NCT00003196) | Fred Hutchinson Cancer Center | 1997-09-01 |
| Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma (NCT00001337) | National Cancer Institute (NCI) | 1993-05-08 |
| High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma (NCT01177371) | Case Comprehensive Cancer Center | 1988-03-01 |